Feb 2013

Home >> Clinical Trials News Archive >> 2013 >> Feb 2013
Record revenues from clinical research for Israel medical centers in 2012: 370 million NIS. The scale of clinical trials in 2012 jumped at Beilinson and Sheba hospitals, and revenues amounted to more than 60 million NIS. Quintiles clinical trials company invested last year the largest amount in Israel – 29.8 million NIS. Teva invested 5.1 million - 40% less than in 2011 (Hebrew).

The British Israel Research and Academic Exchange Partnership (Birax) will grant NIS 25 million (~ US$7 million) over five years for seven joint Israel-UK stem cell research programs.

Israel is in seventh place of 25 countries in the GE Innovation Barometer 2013.This year's survey included more than 3,000 executives.GE publishes its annual barometer ahead of the World Economic Conference in Davos.

Israeli tech startups were bought out for a record total of $5.5 billion in 2012 according to a report by PricewaterhouseCoopers.A report also showed that in 2012 Israel had 50 deals with an average deal size of $111 million, compared with 63 deals with an average size of $81 million in 2011.

FDA offers new guidance on developing drugs for Alzheimer's. The FDA has issued a proposal designed to assist companies developing new treatments for patients in the early stages of Alzheimer's disease, before the onset of noticeable dementia.

April 10: Life Sciences Panel – Making it in NYC. Israel and New York City enjoy a close relationship founded on long-standing economic and cultural ties. On Wednesday, April 10th, representatives from NYC’s Life Sciences sector will discuss opportunities for Israeli companies and organizations to partner with NYC-based companies, organizations and Academic Medical Centers.

IATI-BIOMED June 10-12 to be Crowd-Driven. The Israel Advanced Technology Industry (IATI) is taking the innovation conversation to the next level at its 12th annual IATI-BioMed Conference, and is inviting participants to take the stage and present their latest, most cutting edge developments in Life Sciences to date. For the first time ever, Israeli and international Biomed companies, scientists and entrepreneurs will be given the Chance-To-Speak and present their latest innovations at the IATI BioMed Conference, simply by submitting a 200 word abstract on the topic they wish to showcase.